retatrutide peptide 10 mg 10mg Research (GLP-1/GIP/Glucagon Triple Agonist) Retatrutide 10mg | Canada |

Antimicrob Agents Chemother 1989;33:474-8

1Titration: Week 14: 2 mg once weekly

BMI Standards (Commonly Used Criteria): For weight management purposes, GLP-1 medications are typically considered for individuals with: BMI of 30 or higher (obesity), OR BMI of 27 or higher with at least one weight-related comorbidity (high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, etc.) These are general clinical guidelines used in FDA-approved product labeling and may inform provider decisions

A case series published in Medicine ( Mawardi et al

When GLP-1 medication activates these receptors, it helps suppress appetite by signaling feelings of fullness to the brain, leading to reduced food intake